These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20002783)

  • 1. Lopinavir protein binding in HIV-1-infected pregnant women.
    Aweeka FT; Stek A; Best BM; Hu C; Holland D; Hermes A; Burchett SK; Read J; Mirochnick M; Capparelli EV;
    HIV Med; 2010 Apr; 11(4):232-8. PubMed ID: 20002783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.
    Patterson KB; Dumond JB; Prince HA; Jenkins AJ; Scarsi KK; Wang R; Malone S; Hudgens MG; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 May; 63(1):51-8. PubMed ID: 23221983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced lopinavir exposure during pregnancy.
    Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS
    AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.
    Cressey TR; Van Dyke R; Jourdain G; Puthanakit T; Roongpisuthipong A; Achalapong J; Yuthavisuthi P; Prommas S; Chotivanich N; Maupin R; Smith E; Shapiro DE; Mirochnick M;
    Antimicrob Agents Chemother; 2009 May; 53(5):2189-91. PubMed ID: 19237646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.
    Cressey TR; Jourdain G; Rawangban B; Varadisai S; Kongpanichkul R; Sabsanong P; Yuthavisuthi P; Chirayus S; Ngo-Giang-Huong N; Voramongkol N; Pattarakulwanich S; Lallemant M;
    AIDS; 2010 Sep; 24(14):2193-200. PubMed ID: 20625263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir protein binding in vivo through the 12-hour dosing interval.
    Boffito M; Hoggard PG; Lindup WE; Bonora S; Sinicco A; Khoo SH; Di Perri G; Back DJ
    Ther Drug Monit; 2004 Feb; 26(1):35-9. PubMed ID: 14749547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir exposure with an increased dose during pregnancy.
    Mirochnick M; Best BM; Stek AM; Capparelli E; Hu C; Burchett SK; Holland DT; Smith E; Gaddipati S; Read JS;
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):485-91. PubMed ID: 18989231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.
    Chen J; Malone S; Prince HM; Patterson KB; Dumond JB
    CPT Pharmacometrics Syst Pharmacol; 2016 Mar; 5(3):147-57. PubMed ID: 27069778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M
    Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.
    Ramautarsing RA; van der Lugt J; Gorowara M; Kerr SJ; Burger D; Ruxrungtham K; Phanuphak P; Chaithongwongwatthana S; Avihingsanon A; Phanuphak N
    AIDS; 2011 Jun; 25(10):1299-303. PubMed ID: 21516029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities.
    Peixoto MF; Pilotto JH; Stoszek SK; Kreitchmann R; Mussi-Pinhata MM; Melo VH; João EC; Ceriotto M; Souza Rda S; Read J
    Braz J Infect Dis; 2011; 15(3):253-61. PubMed ID: 21670927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
    Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
    HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
    Else LJ; Douglas M; Dickinson L; Back DJ; Khoo SH; Taylor GP
    Antimicrob Agents Chemother; 2012 Feb; 56(2):816-24. PubMed ID: 22106215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
    Micheli V; Regazzi M; Dickinson L; Meraviglia P; Villani P; Khoo SH; Viganò P; Cordier L; Cusato M; Duca P; Orlando G; Rizzardini G; Back DJ; Cargnel A
    Ther Drug Monit; 2008 Jun; 30(3):306-13. PubMed ID: 18520602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
    Stanley TL; Joy T; Hadigan CM; Liebau JG; Makimura H; Chen CY; Thomas BJ; Weise SB; Robbins GK; Grinspoon SK
    AIDS; 2009 Jul; 23(11):1349-57. PubMed ID: 19474651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen.
    Azria E; Moutafoff C; Schmitz T; Le Meaux JP; Krivine A; Pannier E; Firtion G; Compagnucci A; Finkielsztejn L; Taulera O; Tsatsaris V; Cabrol D; Launay O
    Antivir Ther; 2009; 14(3):423-32. PubMed ID: 19474476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
    Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.